Yale Cancer Center | Strategic Alliance Partners

April 29, 2024

Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.

April 23, 2024

Arianna Gianakos, DO, discusses the innovation in orthobiologics and trailblazing paths in equity and advocacy.

April 12, 2024

Focusing on the KEYNOTE-B61 trial evaluating lenvatinib plus pembrolizumab in the first line, a panel of medical oncologists react to clinical trial data on combination regimens in non–clear cell renal cell carcinoma.

April 12, 2024

Chandler H. Park, MD, highlights cabozantinib monotherapy data from the SWOG 1500 study in non–clear cell renal cell carcinoma.

April 11, 2024

Amin Nassar, MD, discusses the investigation of NGS plus standard IHC to detect dMMR status in patients with colorectal cancer or endometrial cancer.

April 09, 2024

Yale Cancer Center will share data for breakthrough and emerging cancer treatments at the AACR Annual Meeting.

April 05, 2024

The expert panel gives an overview of non–clear cell renal cell carcinoma, highlighting disease subtypes and treatment approaches.

April 05, 2024

Following a review of research on belzutifan in the advanced RCC space, the expert panel has a comprehensive discussion on treatment approaches and toxicity management.

April 04, 2024

Daniel Petrylak, MD, discusses treatment with enfortumab vedotin plus pembrolizumab in patients with urothelial carcinoma in the community setting.

April 03, 2024

Daniel P. Petrylak, MD, discusses the importance of molecularly-driven clinical trials and ongoing research with novel therapeutics in urothelial carcinoma.

March 31, 2024

Daniel P. Petrylak, MD, discusses advancements in the treatment of patients with bladder cancer.

March 29, 2024

Focusing on belzutifan, Laurence Albigès, MD, PhD, reviews data from the LITESPARK-005 clinical trial, and Martin H. Voss, MD, discusses the ongoing LITESPARK-011 trial.

March 29, 2024

Experts on advanced RCC discuss the CONTACT-03 trial evaluating atezolizumab plus cabozantinib following immune checkpoint inhibitor treatment in patients with inoperable disease.

March 28, 2024

Incorporating the Breast Cancer Index test assay into practice affected clinicians’ decision to offer endocrine therapy in HR+ early-stage disease.

March 25, 2024

Amer Zeidan, MBBS, MHS, has been appointed inaugural chief of the Division of Hematologic Malignancies at Yale Cancer Center.

March 22, 2024

David A. Braun, MD, PhD, provides clinical insights on factors that influence treatment decisions in the second line and beyond for patients with advanced clear cell RCC.

March 22, 2024

Focusing on the LITESPARK-003 and LITESPARK-024 trials, Laurence Albigès, MD, PhD, discusses novel doublet regimens under investigation in the first-line setting in advanced renal cell carcinoma.

March 15, 2024

Medical oncologists provide clinical insights on managing adverse events associated with IO-TKI and IO-IO regimens in patients with advanced renal cell carcinoma.

March 15, 2024

The expert panel reacts to 55-month follow-up data from CheckMate 9ER assessing nivolumab plus cabozantinib in patients with newly diagnosed advanced RCC.

March 08, 2024

David A. Braun, MD, PhD, shares his takeaways from the network meta-analysis on lenvatinib plus pembrolizumab in advanced RCC, and Martin H. Voss, MD, discusses outcomes with cabozantinib following frontline lenvatinib plus pembrolizumab.